TABLE 11Most common AEs recorded in patients in the TAnDEM50,a trial

AEsTRA+ANA (n=103)ANA (n=104)
Total (any grade) (%)Grade 3 or higher (%)Total (any grade) (%)Grade 3 or higher (%)
Fatigue211100
Diarrhea20180
Vomiting21351
Arthralgia150101
Pyrexia18070
Back pain15272
Dyspnoea13290
Nausea17150
Cough14060
Headache14060
Nasopharyngitis17020
Bone pain11260
Constipation12050
Chills15100
Hypertension7244
a

Most common AEs are those of any grade occurring at an incidence rate of > 10% in either treatment group and/or those of grade 3 or 4 occurring at a frequency of > 2% in either treatment group.

Note AEs reported in the ANA group were only recorded prior to crossover.

Most common AEs are those of any grade occurring at an incidence rate of > 10% in either treatment group and/or those of grade 3 or 4 occurring at a frequency of > 2% in either treatment group.

From: 3, Assessment of clinical effectiveness

Cover of Lapatinib and Trastuzumab in Combination with an Aromatase Inhibitor for the First-Line Treatment of Metastatic Hormone Receptor-Positive Breast Cancer which Over-Expresses Human Epidermal Growth Factor 2 (HER2): A Systematic Review and Economic Analysis
Lapatinib and Trastuzumab in Combination with an Aromatase Inhibitor for the First-Line Treatment of Metastatic Hormone Receptor-Positive Breast Cancer which Over-Expresses Human Epidermal Growth Factor 2 (HER2): A Systematic Review and Economic Analysis.
Health Technology Assessment, No. 15.42.
Fleeman N, Bagust A, Boland A, et al.
Southampton (UK): NIHR Journals Library; 2011 Dec.
© 2011, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.